||kobe 2602; kobe-2602
||2 years -20¡ãC Powder, 2 weeks4¡ãC in DMSO,6 months-80¡ãC in DMSO
Note: Products for research use only, not for human use
kobe2602 is a novel and effective small-molecule compound inhibiting Ras¨CRaf interaction by SBDD; exhibits potent activity to competitively inhibit the binding of H-Ras¡¤GTP to c-Raf-1 RBD with a Ki value of 149 ¡À 55 ¦ÌM.
IC50 value: 149 ¡À 55 uM (Ki)
These two compounds(Kobe0065 and Kobe2602), added to the culture medium at 2 and 20 ¦ÌM, effectively reduced the amount of c-Raf-1 associated with H-Ras G12V in NIH 3T3 cells in a dose-dependent manner, indicating the inhibition of the cellular activity of Ras. A rough estimate of the IC50 value For the cellular Ras¨CRaf-binding inhibition was around 10 ¦ÌM (Fig. 1B), which was not much different from the Ki values For the in vitro Ras¨CRaf-binding inhibition considering thequite low cellular concentration of Raf. A similar inhibitory effect was also observed with NIH 3T3 cells overexpressing K-Ras G12V. Both Kobe0065 and Kobe2602 at 20 ¦ÌM efficiently inhibited the phosphorylation of MEK and ERK, downstream kinases of Raf in NIH 3T3 cells transiently expressing
H-Ras G12V, although the effect was slightly weaker than that of
2 ¦ÌM sorafenib.For the detailed information of kobe2602, the solubility of kobe2602 in water, the solubility of kobe2602 in DMSO, the solubility of kobe2602 in PBS buffer, the animal experiment (test) of kobe2602, the cell expriment (test) of kobe2602, the in vivo, in vitro and clinical trial test of kobe2602, the EC50, IC50,and Affinity of kobe2602, Please contact DC Chemicals.